Artikel
Lizenziert
Nicht lizenziert
Erfordert eine Authentifizierung
Haemophilia B: From Molecular Diagnosis to Gene Therapy
-
Giuseppe Castaldo
Veröffentlicht/Copyright:
1. Juni 2005
Abstract
Thanks to its typical expression, haemophilia can be identified in writings from the second century AD. Haemophilia B, an X-linked recessive bleeding disorder due to factor IX (FIX) deficiency, has an incidence of about 1:30000 live male births. The factor 9 (F9) gene was mapped in 1984 on Xq27.1. Haemophilia is diagnosed from prothrombin time, activated partial thromboplastin time, and FIX levels. Carrier females are usually asymptomatic and must be identified only with molecular analysis. Linkage analysis of F9 polymorphisms is rapid and inexpensive but limited by non-informative families, recombinant events, and the high incidence of germline mutations; thus, various procedures have been used for the direct scan of F9 mutations. We set up a novel denaturing high performance liquid chromatographic procedure to scan the F9 gene. This rapid, reproducible procedure detected F9 mutations in 100% of a preliminary cohort of 18 haemophilia B patients. Parallel to the development of more efficient diagnostic tools, the life expectancy and reproductive fitness of haemophilic patients have greatly improved and will continue to improve thanks to the use of less immunogenic recombinant FIX. Hopefully, new approaches based on gene therapy now being evaluated in clinical trials will revolutionise haemophilia B treatment.
:
Published Online: 2005-06-01
Published in Print: 2003-04-25
Copyright © 2003 by Walter de Gruyter GmbH & Co. KG
Sie haben derzeit keinen Zugang zu diesem Inhalt.
Sie haben derzeit keinen Zugang zu diesem Inhalt.
Artikel in diesem Heft
- First Santorini Conference: From Genetic Variations to Risk Prediction and Pharmacogenomics
- Pharmacogenetics and Pharmacogenomics in Drug Discovery and Development: An Overview
- Regulatory Gene Mutations Affecting Apolipoprotein Gene Expression: Functions and Regulatory Behavior of Known Genes May Guide Future Pharmacogenomic Approaches to Therapy
- The Proteome: Anno Domini 2002
- Cardiac Sodium Channel Diseases
- Haemophilia B: From Molecular Diagnosis to Gene Therapy
- The Use of Denaturing High-Performance Liquid Chromatography (DHPLC) for the Analysis of Genetic Variations: Impact for Diagnostics and Pharmacogenetics
- Molecular Diagnostics by Microelectronic Microchips
- Molecular Beacons as Diagnostic Tools: Technology and Applications
- Electrochemical DNA Sensor for Detection of Single Nucleotide Polymorphisms
- Comparison of Standard PCR and the LightCycler® Technique to Determine the Thrombophilic Mutations: An Efficiency and Cost Study
- Impact of Purified Water Quality on Molecular Biology Experiments
- Which Are the best Tools for Specific Clinical Application (Chips, Multiplex, Mass Spec Profile, etc.)?
- Genetic Variations Observed in Arterial and Venous Thromboembolism – Relevance for Therapy, Risk Prevention and Prognosis
- The TNF- α Gene NcoI Polymorphism at Position –308 of the Promoter Influences Insulin Resistance, and Increases Serum Triglycerides after Postprandial Lipaemia in Familiar Obesity
- The –308 G/A Tumor Necrosis Factor-α Gene Dimorphism: A Risk Factor for Unstable Angina
- The Apolipoprotein AV Gene and Diurnal Triglyceridaemia in Normolipidaemic Subjects
- Left Ventricular Size, Mass and Function in Relation to Angiotensin-Converting Enzyme Gene and Angiotensin-II Type 1 Receptor Gene Polymorphisms in Patients with Coronary Artery Disease
- Analysis of Multiple Single Nucleotide Polymorphisms of Candidate Genes Related to Coronary Heart Disease Susceptibility by Using Support Vector Machines
- PON1-192 Phenotype and Genotype Assessments in 918 Subjects of the Stanislas Cohort Study
- Lipoprotein Lipase Gene Polymorphisms in Croatian Patients with Coronary Artery Disease
- Homocysteine, Methylenetetrahydrofolate Reductase C677T Polymorphism and the B-Vitamins: A Facet of Nature-Nurture Interplay
- Which, and How Limited Number of Polymorphisms Should Be Selected per Disease, Risk Assessment, Health Profile or Biological System?
- Ethical Issues: Should We Give the Predictive Genetic Profile to the Citizens?
- Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems
- Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine
- Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy
- Pharmacogenomics of Drugs Affecting the Cardiovascular System
- Allele Frequencies for Glutathione S-Transferase and N-Acetyltransferase 2 Differ in African Population Groups and May Be Associated With Oesophageal Cancer or Tuberculosis Incidence
- CYP3A4*1B and NAT2*14 Alleles in a Native African Population
- Pharmacogenetics: From Bench to Bedside
- Meetings and Awards
Artikel in diesem Heft
- First Santorini Conference: From Genetic Variations to Risk Prediction and Pharmacogenomics
- Pharmacogenetics and Pharmacogenomics in Drug Discovery and Development: An Overview
- Regulatory Gene Mutations Affecting Apolipoprotein Gene Expression: Functions and Regulatory Behavior of Known Genes May Guide Future Pharmacogenomic Approaches to Therapy
- The Proteome: Anno Domini 2002
- Cardiac Sodium Channel Diseases
- Haemophilia B: From Molecular Diagnosis to Gene Therapy
- The Use of Denaturing High-Performance Liquid Chromatography (DHPLC) for the Analysis of Genetic Variations: Impact for Diagnostics and Pharmacogenetics
- Molecular Diagnostics by Microelectronic Microchips
- Molecular Beacons as Diagnostic Tools: Technology and Applications
- Electrochemical DNA Sensor for Detection of Single Nucleotide Polymorphisms
- Comparison of Standard PCR and the LightCycler® Technique to Determine the Thrombophilic Mutations: An Efficiency and Cost Study
- Impact of Purified Water Quality on Molecular Biology Experiments
- Which Are the best Tools for Specific Clinical Application (Chips, Multiplex, Mass Spec Profile, etc.)?
- Genetic Variations Observed in Arterial and Venous Thromboembolism – Relevance for Therapy, Risk Prevention and Prognosis
- The TNF- α Gene NcoI Polymorphism at Position –308 of the Promoter Influences Insulin Resistance, and Increases Serum Triglycerides after Postprandial Lipaemia in Familiar Obesity
- The –308 G/A Tumor Necrosis Factor-α Gene Dimorphism: A Risk Factor for Unstable Angina
- The Apolipoprotein AV Gene and Diurnal Triglyceridaemia in Normolipidaemic Subjects
- Left Ventricular Size, Mass and Function in Relation to Angiotensin-Converting Enzyme Gene and Angiotensin-II Type 1 Receptor Gene Polymorphisms in Patients with Coronary Artery Disease
- Analysis of Multiple Single Nucleotide Polymorphisms of Candidate Genes Related to Coronary Heart Disease Susceptibility by Using Support Vector Machines
- PON1-192 Phenotype and Genotype Assessments in 918 Subjects of the Stanislas Cohort Study
- Lipoprotein Lipase Gene Polymorphisms in Croatian Patients with Coronary Artery Disease
- Homocysteine, Methylenetetrahydrofolate Reductase C677T Polymorphism and the B-Vitamins: A Facet of Nature-Nurture Interplay
- Which, and How Limited Number of Polymorphisms Should Be Selected per Disease, Risk Assessment, Health Profile or Biological System?
- Ethical Issues: Should We Give the Predictive Genetic Profile to the Citizens?
- Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems
- Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine
- Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy
- Pharmacogenomics of Drugs Affecting the Cardiovascular System
- Allele Frequencies for Glutathione S-Transferase and N-Acetyltransferase 2 Differ in African Population Groups and May Be Associated With Oesophageal Cancer or Tuberculosis Incidence
- CYP3A4*1B and NAT2*14 Alleles in a Native African Population
- Pharmacogenetics: From Bench to Bedside
- Meetings and Awards
